Cargando…

Metabolic Modifications, Inflammation, and Cancer Immunotherapy

Cancer immunotherapy has accomplished significant progresses on treatment of various cancers in the past decade; however, recent studies revealed more and more heterogeneity in tumor microenvironment which cause unneglectable therapy resistance. A central phenomenon in tumor malignancy is metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Sihao, Song, Qibin, Zhang, Pingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497755/
https://www.ncbi.nlm.nih.gov/pubmed/34631531
http://dx.doi.org/10.3389/fonc.2021.703681
_version_ 1784580022352216064
author Zheng, Sihao
Song, Qibin
Zhang, Pingfeng
author_facet Zheng, Sihao
Song, Qibin
Zhang, Pingfeng
author_sort Zheng, Sihao
collection PubMed
description Cancer immunotherapy has accomplished significant progresses on treatment of various cancers in the past decade; however, recent studies revealed more and more heterogeneity in tumor microenvironment which cause unneglectable therapy resistance. A central phenomenon in tumor malignancy is metabolic dysfunctionality; it reprograms metabolic homeostasis in tumor and stromal cells thus affecting metabolic modifications on specific proteins. These posttranslational modifications include glycosylation and palmitoylation, which usually alter the protein localization, stability, and function. Many of these proteins participate in acute or chronic inflammation and play critical roles in tumorigenesis and progression. Therefore, targeting these metabolic modifications in immune checkpoints and inflammation provides an attractive therapeutic strategy for certain cancers. In this review, we summarize the recent progresses on metabolic modifications in this field, focus on the mechanisms on how glycosylation and palmitoylation regulate innate immune and inflammation, and we further discuss designing new immunotherapy targeting metabolic modifications. We aim to improve immunotherapy or targeted-therapy response and achieve more accurate individual therapy.
format Online
Article
Text
id pubmed-8497755
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84977552021-10-09 Metabolic Modifications, Inflammation, and Cancer Immunotherapy Zheng, Sihao Song, Qibin Zhang, Pingfeng Front Oncol Oncology Cancer immunotherapy has accomplished significant progresses on treatment of various cancers in the past decade; however, recent studies revealed more and more heterogeneity in tumor microenvironment which cause unneglectable therapy resistance. A central phenomenon in tumor malignancy is metabolic dysfunctionality; it reprograms metabolic homeostasis in tumor and stromal cells thus affecting metabolic modifications on specific proteins. These posttranslational modifications include glycosylation and palmitoylation, which usually alter the protein localization, stability, and function. Many of these proteins participate in acute or chronic inflammation and play critical roles in tumorigenesis and progression. Therefore, targeting these metabolic modifications in immune checkpoints and inflammation provides an attractive therapeutic strategy for certain cancers. In this review, we summarize the recent progresses on metabolic modifications in this field, focus on the mechanisms on how glycosylation and palmitoylation regulate innate immune and inflammation, and we further discuss designing new immunotherapy targeting metabolic modifications. We aim to improve immunotherapy or targeted-therapy response and achieve more accurate individual therapy. Frontiers Media S.A. 2021-09-24 /pmc/articles/PMC8497755/ /pubmed/34631531 http://dx.doi.org/10.3389/fonc.2021.703681 Text en Copyright © 2021 Zheng, Song and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zheng, Sihao
Song, Qibin
Zhang, Pingfeng
Metabolic Modifications, Inflammation, and Cancer Immunotherapy
title Metabolic Modifications, Inflammation, and Cancer Immunotherapy
title_full Metabolic Modifications, Inflammation, and Cancer Immunotherapy
title_fullStr Metabolic Modifications, Inflammation, and Cancer Immunotherapy
title_full_unstemmed Metabolic Modifications, Inflammation, and Cancer Immunotherapy
title_short Metabolic Modifications, Inflammation, and Cancer Immunotherapy
title_sort metabolic modifications, inflammation, and cancer immunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497755/
https://www.ncbi.nlm.nih.gov/pubmed/34631531
http://dx.doi.org/10.3389/fonc.2021.703681
work_keys_str_mv AT zhengsihao metabolicmodificationsinflammationandcancerimmunotherapy
AT songqibin metabolicmodificationsinflammationandcancerimmunotherapy
AT zhangpingfeng metabolicmodificationsinflammationandcancerimmunotherapy